Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

GLUE - Monte Rosa Therapeutics Inc


IEX Last Trade
6.15
-0.240   -3.902%

Share volume: 222,878
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$6.39
-0.24
-3.76%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
4%
Profitability 0%
Dept financing 0%
Liquidity 0%
Performance 10%
Performance
5 Days
-2.53%
1 Month
37.72%
3 Months
49.76%
6 Months
0.49%
1 Year
-1.75%
2 Year
-22.00%
Key data
Stock price
$6.15
P/E Ratio 
0.00
DAY RANGE
N/A - N/A
EPS 
$0.00
52 WEEK RANGE
$2.44 - $8.84
52 WEEK CHANGE
-$0.00
MARKET CAP 
378.670 M
YIELD 
N/A
SHARES OUTSTANDING 
61.373 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/07/2024
BETA 
2.55
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$284,387
AVERAGE 30 VOLUME 
$222,063
Company detail
CEO:
Region: US
Website: monterosatx.com
Employees: 123
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

small molecule protein degraders are set to reshape the way by which diseases will be treated. our rational approach in targeting disease-causing proteins for degradation will deliver pioneering therapies for cancer and beyond. headquartered in boston with additional laboratory facilities in basel, monte rosa therapeutics is a private company launched in 2020. initially seeded by versant ventures and incubated at ridgeline discovery in basel, and the institute of cancer research in london, monte rosa has raised $32.5 million from versant and new enterprise associates. academic co-founders are prof. raj chopra and prof. ian collins of the institute for cancer research, uk.

Recent news